A tiny skin device to test medicines for psoriasis and eczema
Tests a small skin device that releases drug doses in adults with psoriasis or eczema.
Plain-language title generated from the registry record
Registry title: Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of California San FranciscoSan Francisco, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT07352566
- Record updated
- 3 June 2026
- Original description
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.Read full original descriptionShow less
Utilization of a Cutaneous Therapy In Situ Microdevice
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Inclusion: > 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days).